Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
GlaxoSmithKline will purchase Tesaro, which sells a PARP inhibitor cancer drug, for $5.1 billion. Niraparib, sold under the name Zejula, inhibits an enzyme involved in DNA repair called poly(ADP-ribose) polymerase, or PARP. Blocking PARP-mediated DNA repair in tumors that already have a gene mutation can deal the tumors a fatal blow. In the first three quarters of 2018, Tesaro posted only $166 million in niraparib sales, but GSK is counting on revenues to increase in the future.
This article has been sent to the following recipient: